https://www.frontiersin.org/journals/stroke RSS Feed for Frontiers in Stroke | New and Recent Articles en-us Frontiers Feed Generator,version:1 2026-10-05T16:47:08.626+00:00 60 https://www.frontiersin.org/articles/10.3389/fstro.2026.1952839 https://www.frontiersin.org/articles/10.3389/fstro.2026.1952839 2026-09-30T00:00:00Z Case Report Shuichi SasakiNaonobu TakahiraYuzo OnoKeiichiro AokiSora KurosakiMarina MotekiRisa FujitaTomonori Kenmoku https://www.frontiersin.org/articles/10.3389/fstro.2026.1908099 https://www.frontiersin.org/articles/10.3389/fstro.2026.1908099 2026-09-28T00:00:00Z Original Research Fadi ShbatKarine Beiruti WieglerNajib DallyElias SaadSaher SrourElizabeth EshelAdi Sharabi NovRadi ShahienRonen LekerNaaem Simaan https://www.frontiersin.org/articles/10.3389/fstro.2026.1894659 https://www.frontiersin.org/articles/10.3389/fstro.2026.1894659 2026-09-28T00:00:00Z Original Research Majid Khalili-ArdaliVivek SharmaTarandeep Singh MandaharFrancisco Páscoa dos SantosPaul TiesingaNick Ramsey https://www.frontiersin.org/articles/10.3389/fstro.2026.1850977 https://www.frontiersin.org/articles/10.3389/fstro.2026.1850977 2026-09-24T00:00:00Z Original Research Emily A. StevensLexie J. PfeiferMatt P. Malcolm https://www.frontiersin.org/articles/10.3389/fstro.2026.1946990 https://www.frontiersin.org/articles/10.3389/fstro.2026.1946990 2026-09-24T00:00:00Z Original Research Marieta PeychevaCharlotte BergerMarino CostaLee SiegenthalerFiona HuberIsmaël RizzoMarina KrastevaMorin BeyelerTatiana Bremova-ErtlNedelina SlavovaPasquale MordasiniRoza M. UmarovaPhilipp BückeKateryna AntonenkoAngelika HoffmannSara Pilgram-PastorMirjam R. Heldner https://www.frontiersin.org/articles/10.3389/fstro.2026.1978900 https://www.frontiersin.org/articles/10.3389/fstro.2026.1978900 2026-09-22T00:00:00Z Editorial Hipólito NzwaloMiguel BarbozaNicola Logallo https://www.frontiersin.org/articles/10.3389/fstro.2026.1890618 https://www.frontiersin.org/articles/10.3389/fstro.2026.1890618 2026-09-21T00:00:00Z Review Takahiro Ota https://www.frontiersin.org/articles/10.3389/fstro.2026.1916617 https://www.frontiersin.org/articles/10.3389/fstro.2026.1916617 2026-09-21T00:00:00Z Original Research Laura Sofía García-EspinosaÁngel Basilio Corredor-QuinteroRicardo Andrés Lineros-FrancoAdriana Hernández-CardonaIvett Natalia Loaiza-GiraldoFelipe Torres-GómezJorge Luis Igirio-Gamero https://www.frontiersin.org/articles/10.3389/fstro.2026.1897859 https://www.frontiersin.org/articles/10.3389/fstro.2026.1897859 2026-09-15T00:00:00Z Brief Research Report Torsten RackollLea DoppelbauerKonrad NeumannAlexander Heinrich Nave https://www.frontiersin.org/articles/10.3389/fstro.2026.1967379 https://www.frontiersin.org/articles/10.3389/fstro.2026.1967379 2026-09-15T00:00:00Z Editorial Gabriel BroocksPanagiotis PapanagiotouLeonard L. L. YeoAnil GopinathanEytan RazLukas Meyer https://www.frontiersin.org/articles/10.3389/fstro.2026.1903852 https://www.frontiersin.org/articles/10.3389/fstro.2026.1903852 2026-09-03T00:00:00Z Original Research Chung-Huan SunIan ChunKazuma NakagawaStacy BrownSamuel TsappidiFerdinand HuiYi ZhangRony SalemGuangxiang ZhangDaniel GalanisMatthew Koenig https://www.frontiersin.org/articles/10.3389/fstro.2026.1918465 https://www.frontiersin.org/articles/10.3389/fstro.2026.1918465 2026-08-25T00:00:00Z Perspective Håkon Ihle-HansenHege Ihle-HansenRolf A. BlauenfeldtJesse DawsonSøren Z. DiederichsenGuri Hagberg https://www.frontiersin.org/articles/10.3389/fstro.2026.1913292 https://www.frontiersin.org/articles/10.3389/fstro.2026.1913292 2026-08-24T00:00:00Z Original Research Ronald BwambaleRonald SsenyongaMark KaddumukasaMartha SajatovicAggrey David Mukose https://www.frontiersin.org/articles/10.3389/fstro.2026.1845862 https://www.frontiersin.org/articles/10.3389/fstro.2026.1845862 2026-08-21T00:00:00Z Original Research Haroon KhanYang WangJing ChenXiao-Bing XieWei XuMeng LiDong-Ling HuangJiannan XiaoChuan-Cheng Ren https://www.frontiersin.org/articles/10.3389/fstro.2026.1879025 https://www.frontiersin.org/articles/10.3389/fstro.2026.1879025 2026-08-21T00:00:00Z Original Research Ayush AgarwalChristine TunklAlexandra KraussEmily R. RamageMirjam R. HeldnerStefan T. GernerTeresa UllbergLeonardo A. CarboneraJatinder S. MinhasAristeidis KatsanosMatias J. AletAbdul H. K. Y. KhanFaddi Saleh ValezTamer RoushdyLinxin LiBogdan CiopleiasZhe Kang LawRadhika LotlikarSusanna M. ZuurbierMaria G. MosconiShirsho ShreyanShakti ShresthaGisele S. SilvaAnnemarei Ranta https://www.frontiersin.org/articles/10.3389/fstro.2026.1840317 https://www.frontiersin.org/articles/10.3389/fstro.2026.1840317 2026-08-14T00:00:00Z Original Research Jin Un KimZhen CahilogZehra KadaniTeledalase OlajoyegbeDarren FernandesDhiraj AilKarishma OojageerTelma Da SilvaSaeedur RahmanPeter Kabunga https://www.frontiersin.org/articles/10.3389/fstro.2026.1847419 https://www.frontiersin.org/articles/10.3389/fstro.2026.1847419 2026-08-14T00:00:00Z Original Research Eva Birgitte AamodtKarim BoreiThomas PotterFarhaan Vahidy https://www.frontiersin.org/articles/10.3389/fstro.2026.1915602 https://www.frontiersin.org/articles/10.3389/fstro.2026.1915602 2026-08-14T00:00:00Z Systematic Review Ahmed AljabaliDeema AlhayaliHallie Taylor-WedgeTodd A. LaffayeMajd Al-AhmedAyham HarahshehMohammed AlamoushKhaled DweikMayowa A. OsundijiAmir A. MbondeCumara B. O'CarrollBart M. DemaerschalkEhab Harahsheh 2 territories) were observed in 65%. Conventional vascular risk factors were infrequent (0%−21%), whereas deep vein thrombosis (43%) and systemic embolism (41%) frequently preceded or coincided with stroke onset. Malignancy (70%) and autoimmune disease (25%) were the main NBTE etiologies. Anticoagulation was initiated in 70%, and 21% underwent valvular surgery. Over a median follow-up of 2.0 months, stroke recurred in 43% and death occurred in 49% of patients. Malignant etiology (aOR 10.3, P < 0.001) and metastases (aOR 3.9, P < 0.001) were associated with increased mortality, while VKA use (aOR 0.08, P < 0.001) and autoimmune etiology (aOR 0.1, P < 0.001) were associated with lower mortality. Malignancy (aOR 2.8, P < 0.001) and DOAC use (aOR 5.2, P = 0.012) were associated with increased risk of recurrent stroke.ConclusionNBTE should be considered in stroke patients lacking conventional vascular risk factors, particularly those with malignancy or autoimmune disease. Malignancy and DOAC use were associated with higher recurrent stroke risk, while VKA use was associated with lower mortality; however, these anticoagulant-class findings should be considered hypothesis-generating and interpreted cautiously given the case-report evidence base, small treatment subgroups, potential confounding, and limited follow-up.What this study addsBy synthesizing patient-level data from published case reports and case series, this review provides a stroke-focused characterization of NBTE, including clinical presentation, infarct topography, underlying etiologies, management strategies, recurrent cerebrovascular events, and mortality. The findings highlight multifocal infarction, malignancy-associated NBTE, and recurrent stroke despite anticoagulation as key clinical concerns, while emphasizing that observed associations with anticoagulant class should be viewed as hypothesis-generating rather than definitive treatment guidance]]> https://www.frontiersin.org/articles/10.3389/fstro.2026.1800285 https://www.frontiersin.org/articles/10.3389/fstro.2026.1800285 2026-08-07T00:00:00Z Original Research Yingxia LiRuixing ZhangYang LuoYouquan Gu 2.86 indicated a higher risk of poor short-term functional status.ConclusionsAdmission levels of DBIL and DBLR are significantly correlated with the degree of neurological impairment and short-term (7 ± 2 days) in-hospital functional status in AIS patients, where higher values indicate more severe acute neurological deficits and poorer early outcomes. Elevated DBLR is independently associated with poor short-term functional status, and the exploratory cutoff of DBLR > 2.86 (OR = 5.169, 95% CI: 1.623–16.461, P = 0.005) may assist in early risk stratification. However, their independent predictive ability is limited (all AUCs < 0.7). Therefore, these biomarkers should only be used as auxiliary tools in combination with clinical scores such as the NIHSS, and their clinical value should not be overinterpreted.]]> https://www.frontiersin.org/articles/10.3389/fstro.2026.1861562 https://www.frontiersin.org/articles/10.3389/fstro.2026.1861562 2026-07-31T00:00:00Z Review Jin YangTing WangYaoyue HuCuiying LiuTianliang ShiHeng Zhao